**Title:** Homocysteine Testing

**Professional**
Original Effective Date: March 13, 2009
Revision Date(s): August 17, 2010; August 12, 2011; June 29, 2012; March 31, 2014; February 24, 2016; October 1, 2016; October 1, 2017
Current Effective Date: August 17, 2010

**Institutional**
Original Effective Date: March 13, 2009
Revision Date(s): September 16, 2010; August 12, 2011; June 29, 2012; March 31, 2014; February 24, 2016; October 1, 2016; October 1, 2017
Current Effective Date: September 16, 2010

State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member’s benefits, contact Blue Cross and Blue Shield of Kansas Customer Service.

The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.

The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.

If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.

<table>
<thead>
<tr>
<th>Populations</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individuals: • Who are asymptomatic with risk of cardiovascular disease</td>
<td>Interventions of interest are: • Homocysteine testing</td>
<td>Comparators of interest are: • Routine care without homocysteine testing</td>
<td>Relevant outcomes include: • Test accuracy • Test validity • Other test performance measures • Change in disease status • Morbid events</td>
</tr>
</tbody>
</table>

| Individuals: • With cardiovascular disease | Interventions of interest are: • Homocysteine testing | Comparators of interest are: • Routine care without homocysteine testing | Relevant outcomes include: • Test accuracy • Test validity • Other test performance measures • Change in disease status • Morbid events |
DESCRIPTION
Homocysteine is an amino acid found in the blood, which has been evaluated as a potential marker of cardiovascular disease (CVD) in the general population and as a potential risk marker among people with CVD. The association between homocysteine-lowering interventions and risk of CVD has also been examined.

Background
Homocysteine is a sulfur-containing amino acid that is rapidly oxidized in plasma into homocysteine and cysteine-homocysteine disulfide. Measurement of total plasma homocysteine is the sum of homocysteine and its oxidized forms. The laboratory test is referred to as either homocysteine or homocyst(e)ine.

Plasma levels of homocysteine have been actively researched as a risk factor for cardiovascular disease (CVD), initially based on the observation that patients with hereditary homocystinuria, an inborn error of metabolism associated with high plasma levels of homocysteine, had a markedly increased risk of CVD. Subsequently, prospective epidemiologic studies were conducted to determine if an elevated plasma level of homocysteine was an independent risk factor for CVD and could be used to improve current risk prediction models.

Interest in homocysteine as a potentially modifiable risk factor has been stimulated by the epidemiologic finding that levels of homocysteine are inversely correlated with levels of folate. This finding has raised the possibility that treatment with folic acid might lower homocysteine levels and, in turn, reduce the risk of CVD. Therefore, homocysteine has potential utility both as a risk predictor and as a target of treatment.

Determination of homocysteine concentration may be offered as a component of a comprehensive cardiovascular risk assessment that may include evaluation of small-density lipoproteins, subclassification of high-density lipoproteins, evaluation of lipoprotein (a), high-sensitivity C-reactive protein, and genotyping of apolipoprotein E.

Regulatory Status
Several homocysteine test systems have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. These include the liquid-stable 2-part homocysteine reagent test by Catch Inc. (Maple Valley, WA) in 2006. Catch Inc. was purchased by Axis-Shield (Scotland) in 2010 and the Catch-branded products were phased out in 2011. The test is indicated for the in vitro quantitative determination of total homocysteine in serum and plasma to assist in diagnosing and treating patients with suspicion of homocystinuria and hyperhomocysteinemia. Other homocysteine test systems cleared for marketing by FDA include the Homocysteine Enzymatic Assay (Roche Diagnostics, Indianapolis, IN) in 2012, the Diazyme Enzymatic Homocysteine Assay (Diazyme Laboratories, Poway, CA) in 2012, the A/C Automatic Enzymatic Hcy [Homocysteine] Assay (AntiCancer Inc., San Diego, CA) in 2008, and the Teco Enzymatic Homocysteine Assay (Teco Diagnostics, Anaheim, CA) in 2007. FDA product code: LPS.
POLICY

I. Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease

Measurement of plasma levels of homocysteine is considered experimental / investigational in the screening, evaluation, and management of patients for cardiovascular disease.

II. Other Homocysteine Testing

A. Homocysteine Testing may be considered medically necessary for non-cardiovascular diagnoses of:
   1. homocystinuria
   2. recurrent pregnancy loss
   3. borderline vitamin B 12 deficiency
   4. venous thromboembolism

B. Homocysteine Testing is considered experimental / investigational for any other diagnoses.

RATIONALE

This evidence review has been updated with searches of the MEDLINE database. The most recent literature update was performed through November 9, 2015. Following is a summary of the key literature to date.

Homocysteine testing can be evaluated in a similar framework as other novel cardiac risk factors. There are several conditions that must be met for a cardiovascular risk factor to demonstrate clinical utility. A 2002 TEC Assessment\(^1\) summarized 3 steps necessary for clinical utility:

- Standardization of measurement of the risk factor.
- Determination of its contribution to risk assessment. As a risk factor, it is important to determine whether the novel risk factor contributes independently to risk assessment compared with established risk factors.
- Determination of how the novel risk factor will be used in the management of the patient, compared with standard methods of assessing risk, and whether any subsequent changes in patient management result in an improvement in patient outcomes.

Is Measurement of Homocysteine Standardized?
There are U.S. Food and Drug Administration–cleared commercially available kits for measuring homocysteine.

Is Homocysteine an Independent Risk Factor for Cardiovascular Disease?
In 2002, the Homocysteine Studies Collaboration published a meta-analysis of observational studies evaluating the association between homocysteine concentration and risk of ischemic heart disease (IHD) or stroke.\(^2\) A total of 30 studies were identified that had individual patient
data available; this included 18 retrospective studies and 13 prospective studies. In the prospective studies, blood for measuring homocysteine concentration was collected before the clinical onset of disease. The adjusted odds ratio (OR) of ischemic heart disease associated with a 25% lower homocysteine level was 0.83 (95% confidence interval [CI], 0.77 to 0.89) in prospective studies, 0.67 (95% CI, 0.62 to 0.71) in retrospective studies using population controls, and 0.73 (95% CI, 0.64 to 0.83) in retrospective studies with other controls. The adjusted OR of stroke associated with a 25% lower homocysteine level was 0.77 (95% CI, 0.66 to 0.90) in prospective studies, 0.86 (95% CI, 0.73 to 1.01) in retrospective studies with population controls, and 0.46 (95% CI, 0.30 to 0.70) in retrospective studies with other controls. The risk of IHD and stroke was significantly weaker in the prospective studies than the retrospective studies, which may reflect biases in retrospective studies.

Subsequent meta-analyses of observational studies have found significant associations between homocysteine and morbidity and mortality, including a 2015 meta-analysis of 12 studies, which found increased coronary artery disease (CAD), cardiovascular, and all-cause mortality with higher homocysteine levels.

Among the prospective studies included in the Homocysteine Studies Collaboration meta-analysis was one by Folsom et al that identified patients who developed coronary heart disease (CHD) among an initial cohort of 15,792 patients participating in the Atherosclerosis Risk in Communities (ARIC) trial. The median follow-up time was 3.3 years. Plasma homocysteine was evaluated from the stored blood samples of the 232 patients plus a random sample of the rest of the cohort. While homocysteine was a significant univariate predictor of CAD, this association was not significant after adjusting for other cardiac risk factors in multivariate analysis. Another prospective study was published by Evans et al. The investigators identified 240 cases of nonfatal myocardial infarction (MI) or coronary death among a cohort of 12,866 men participating in the Multiple Risk Factor Intervention Trial (MRFIT). Homocysteine from stored blood samples from these patients plus 472 control patients were evaluated. With a follow-up ranging from 11 to 17 years, homocysteine levels did not appear to be an independent risk factor for CHD. In contrast, in a nested case-control study derived from a prospective cohort study of 21,520 men enrolled in the British United Provident Study, Wald et al reported that the initial stored plasma level of homocysteine was significantly higher among 229 men who ultimately died of IHD compared with a control group of 1126 men who did not die of IHD and did not have a history of IHD.

Since publication of the Homocysteine Studies Collaboration meta-analysis, a number of studies have reported on the association between homocysteine and various types of cardiovascular disease (CVD). Representative studies are described in Table 1.
<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Outcome(s) Evaluated</th>
<th>Major Findings</th>
</tr>
</thead>
</table>
| Park et al (2010)⁷    | 6371 individuals ages 40-79 y without history of MI, stroke, or PAD; 3860 (61%) with homocysteine level available | 10-y CVD risk based on Framingham score:  
  - Low risk (n=2527)  
  - Intermediate risk (n=3336)  
  - High risk (n=508) | ▪ Homocysteine levels at ≥85th percentile associated with high Framingham risk score: OR=2.1 (95% CI, 1.48 to 3.01)  
  ▪ Homocysteine levels at ≥85th percentile not significantly associated with intermediate Framingham risk score: OR=1.11 (95% CI, 0.89 to 1.38) |
| Wang et al (2014)⁸    | 5935 individuals with hypertension enrolled in a population-based prospective cohort study | Incident ischemic stroke  
  ▪ CHD | ▪ Homocysteine levels ≥30 µmol/L (vs <15 µmol/L) associated with higher ischemic stroke rates after adjusting for ischemic stroke risk factors: OR=2.86 (95% CI, 1.72 to 4.75)  
  ▪ Homocysteine levels ≥30 µmol/L (vs <15 µmol/L) not associated with CHD |
| Han et al (2015)⁹     | 5488 individuals with follow-up available from population-based prospective cohort study of 5935 hypertensive individuals | Incident ischemic stroke | ▪ Homocysteine levels ≥15 µmol/L associated with higher ischemic stroke rates: HR=2.18 (95% CI, 1.65 to 2.89)  
  ▪ Among 501 subjects who took folic acid supplementation, plasma homocysteine levels declined an average 6.7 µmol/L (clinical outcomes not reported separately) |
| Wang et al (2015)¹⁰   | 200 cases with hypertension and ischemic stroke, vs 400 age-matched controls with hypertension and without ischemic stroke | Incident stroke | After adjusting for ischemic stroke risk factors, total homocysteine associated with ischemic stroke among women but not men:  
  ▪ Women: OR for stroke (comparing highest with lowest total homocysteine quartile), 4.51 (95% CI, 1.29 to 15.7)  
  ▪ Men: OR for stroke, 0.83 (95% CI, 0.36 to 1.90) |
| Catena et al (2015)¹¹ | 562 consecutive patients with hypertension evaluated at a single center | Prevalence of:  
  ▪ Metabolic syndrome  
  ▪ CHD  
  ▪ Cerebrovascular disease | After adjustment for confounding variables, homocysteine significantly associated with:  
  ▪ Presence of metabolic syndrome: OR=1.01 (95% CI, 1.00 to 1.02; p=0.02)  
  ▪ Presence of cerebro-/cardiovascular disease: OR=1.011 (95% CI, 1.00 to 1.02; p=0.01) |
| Sheng et al (2015)¹²   | 1680 subjects with arterial stiffness measurements enrolled in a community-based cross-sectional study | Vascular function measurements:  
  ▪ CF-PWV  
  ▪ CA-PWV  
  ▪ Heart rate-corrected AI | Homocysteine levels positively correlated with:  
  ▪ CF-PWV:  r=0.211 (p<0.001)  
  ▪ CA-PWV:  r=0.148 (p<0.001)  
  Levels negatively correlated with AI:  r = -0.052 (p=0.016) |
Shi et al (2015)\textsuperscript{13}  3799 adults with ischemic stroke enrolled a single hospital in China  Poststroke mortality  Among 223 patients who died during follow-up, those with highest 3rd and 4th quartiles of homocysteine had higher risk of stroke death, after adjusting for confounding variables:

- 3th vs 1st quartile: adjusted HR=2.27 (95% CI, 1.06 to 4.86; \( p=0.029 \))
- 4th vs 1st quartile: adjusted HR=2.15 (95% CI, 1.01 to 4.63; \( p=0.049 \))

For patients with known CVD, prospective data more consistently demonstrate that homocysteine is a risk factor for future events. In 1997, for example, Nygard et al reported on a prospective study of the plasma homocysteine levels in 587 patients with angiographically confirmed CAD.\textsuperscript{14} After a median follow-up of 4.6 years, the authors compared the initial homocysteine levels of the 64 patients (10.9%) who had died with those of the remaining 523 survivors. The authors reported a strong graded dose-response relationship between plasma homocysteine and mortality. In addition, Knekt et al reported the outcomes at 13-year follow-up for 3471 middle-aged Finnish men, 884 of whom had known CVD at baseline.\textsuperscript{15} Using the homocysteine values from stored blood samples, a strong positive correlation was noted between homocysteine concentration and subsequent major coronary events in men with known CVD at baseline. However, investigators found no association between serum homocysteine concentration and the incidence of major coronary events (death from CHD or nonfatal MI) among men originally free of heart disease.

In 2011, Veeranna et al published a post hoc analysis of national survey databases to evaluate whether adding homocysteine to the Framingham risk score model improves risk classification.\textsuperscript{16} The data were taken from the nationally representative surveys Multi-Ethnic Study of Atherosclerosis (MESA), which included subjects between the ages of 45 and 84 years with no prior history of CVD and the National Health and Nutrition Survey III (NHANES III), a sample of noninstitutionalized subjects. Homocysteine level was associated with CVD risk in both databases. In a receiver-operating curve analysis, the area under the curve (AUC) for predicting CHD events in the MESA database was 0.74 using the Framingham risk score and 0.76 when homocysteine level was added to the Framingham score. The improvement in risk prediction was statistically significant (\( p<0.001 \)). The AUC for predicting CHD deaths in NHANES III was 0.84 using the Framingham risk score alone and 0.87 when homocysteine level was added to the Framingham score; this difference was statistically significant (\( p<0.001 \)). Adding homocysteine to the Framingham model resulted in reclassification of 832 (12.9%) subjects in the MESA cohort and 1243 (18%) in the NHANES III cohort. This study does not address whether testing for homocysteine would improve health outcomes.

**Section Summary: Homocysteine as an Independent Risk Factor for Cardiovascular Disease**

A meta-analysis of observational studies found a statistically significant moderate association between homocysteine levels and risk of CVD. Studies have also found a significant correlation between homocysteine levels in patients with known CVD and subsequent coronary events. One study analyzing nationally representative survey data found that adding homocysteine level to the Framingham risk score significantly improved risk prediction. Overall, the available evidence...
suggests that homocysteine levels are associated with increased risk of a variety of cardiovascular disorders and outcomes among patients with existing CVD.

**Will Identification of Homocysteine Level Lead to Changes in Patient Management, and Will These Changes in Management Lead to Improved Patient Outcomes?**

Vitamin B and folic acid supplementation are potential interventions that could be used for patients with homocysteine levels to improve health outcomes. However, public health measures are already in place that require all enriched grain products be fortified with folic acid to reduce the risk of neural tube defects in newborns. This fortification has been associated with a decrease in plasma homocysteine concentration in a population-representative adult sample.\(^1\) Trials evaluating the impact of homocysteine-lowering therapy on health outcomes should thus evaluate the utility of treatments that lower homocysteine levels beyond those achieved by these general public health measures. In addition, clear target levels for homocysteine concentration would need to be established for translating information on homocysteine lowering into clinical practice.

Numerous randomized controlled trials (RCTs) have been published that provide evidence on the benefit of vitamin therapy to reduce homocysteine levels and prevent cardiovascular events. Moreover, several meta-analyses have synthesized the available RCT evidence on this question.

**Systematic Reviews**

In 2015, a Cochrane systematic review, originally published in 2009 and updated in 2013,\(^1\) on the effectiveness of homocysteine-lowering interventions for preventing cardiovascular events, including both MI and stroke, was updated.\(^1\) The review included RCTs assessing the effects of homocysteine-lowering interventions for preventing cardiovascular events with at least 1 year of follow-up and considered MI and stroke as the primary outcomes. No new trials published since the last update were identified. Twelve trials with a total of 47,429 subjects met eligibility criteria. Nine of the studies included more than 1,000 participants. Nine studies used placebo controls, 2 used usual care controls, and 1 compared high and low doses of homocysteine-lowering therapy. In a pooled analysis of 11 trials, there was no statistically significant difference in nonfatal or fatal MI between intervention and control groups (relative risk [RR], 1.02; 95% CI, 0.95 to 1.10). In a pooled analysis of 9 studies, there was no significant difference between groups in the rate of nonfatal or fatal stroke (RR=0.91; 95% CI, 0.82 to 1.00). There was also no significant mortality benefit in groups assigned to homocysteine-lowering therapy. For mortality of any cause, the relative risk was 1.01 (95% CI, 0.96 to 1.07) in a meta-analysis of data from 10 trials.

In 2011 Zhou et al conducted a systematic review of double-blind placebo-controlled RCTs evaluating the impact of folic acid supplementation on cardiovascular outcomes.\(^2\) Interventions were included whether or not they involved supplementation with vitamin B in addition to folic acid. The review was limited to trials that included at least 100 patients and had at least 6 months of follow-up. Of 66 articles retrieved for detailed inspection, 16 trials with data on 44,841 patients met the review's inclusion criteria. In a meta-analysis of findings from 12 trials, folic acid supplementation was not found to have a significant effect on major cardiovascular events compared with placebo (RR=0.98; 95% CI, 0.93 to 1.04). In addition, folic acid supplementation did not have a significant effect on individual outcomes including stroke (12 trials; RR=0.89; 95% CI, 0.78 to 1.01), MI (11 trials; RR=1.00; 95% CI, 0.93 to 1.07), or all-cause mortality (14 trials; RR=1.00, 95% CI, 0.96 to 1.05).
Also in 2011, Clarke et al published a meta-analysis of placebo-controlled homocysteine-lowering RCTs. This meta-analysis was limited to studies that included at least 1000 participants and have at least 1 year of follow-up. A total of 8 trials with 37,485 individuals met the review's inclusion criteria. In a pooled analysis of findings from the 8 trials, vitamin B supplementation did not have a significant effect on risk of CHD events compared with placebo (RR=1.01; 95% CI, 0.96 to 1.07). In addition, in pooled analyses of data from the 8 trials, vitamin B supplementation was not found to have a significant effect on stroke events (RR=0.96; 95% CI, 0.87 to 1.07), cancer events (RR=1.08; 95% CI, 0.99 to 1.17), or all-cause mortality (RR=1.02; 95% CI, 0.97 to 1.07).

A fourth meta-analysis, published in 2012 by Huang et al, included RCTs evaluating B vitamin supplementation in patients with preexisting vascular disease. This review had more lenient inclusion criteria, as there was no limitation on study size or intervention duration. A total of 19 trials with 47,921 patients were included in the meta-analysis. Unlike the other meta-analyses previously discussed, in a pooled analysis of study data, the authors found a statistically significant benefit of vitamin B supplementation on stroke (RR=0.88; 95% CI, 0.82 to 0.95). Similar to the other meta-analyses, vitamin B supplementation was not found to have a statistically significant impact on other outcomes, including CHD, MI, and all-cause mortality. Given the more relaxed entry criteria, the meta-analysis may have included some lower-quality studies; the authors did not present a formal analysis of trial quality.

A 2014 meta-analysis included RCTs that compared folic acid supplementation (at least 5 mg/d for at least 4 weeks), without vitamin B supplementation, with placebo and evaluated endothelial function and homocysteine level as outcomes in patients with CAD. A total of 6 trials with 377 subjects were included. In pooled analysis, folic acid supplementation was associated with increased flow-mediated dilation (FMD), a noninvasive, ultrasound-based method to assess vascular endothelial function (mean difference (MD), 57.72 μm; 95% CI, 50.14 to 65.3; p<0.05). Folic acid supplementation was also associated with reduced plasma homocysteine concentration (MD = -3.66 μmol/L; 95% CI, -5.44 to -7.87; p<0.05). For other measures of endothelial function, there was no significant change in the response to end diastolic diameter, glyceryl-trinitrate diameter, heart rate, baseline and peak hyperemic flow, and systolic and diastolic blood pressure between the folic acid and placebo groups.

Liu et al also reported results of a meta-analysis of placebo-controlled RCTs that evaluated the effect of homocysteine-lowering therapies on FMD in patients with CAD. A total of 8 studies with 611 subjects were included; folic acid doses ranged from 400 to 10,000 μg/d. In pooled analysis, folic acid supplementation was associated with improved FMD compared with placebo (standardized MD=1.65; 95% CI, 1.12 to 2.17; p<0.001), but there was significant heterogeneity across studies.

Randomized Controlled Trials
Representative RCTs evaluating homocysteine-lower interventions are described next.

The HOPE-2 trial included 5522 patients with preexisting vascular disease. Patients were randomized to treatment with a regimen of folate, vitamin B₆, and vitamin B₁₂ or placebo and followed up for an average of approximately 5 years. There were no significant differences in the composite outcome of cardiovascular death, MI, or stroke (RR=0.95; 95% CI, 0.84 to 1.07). However, there was a significant decrease in the risk of stroke for patients in the treatment group (RR=0.75; 95% CI, 0.59 to 0.97; p=0.03). For the secondary outcome of hospitalization
for unstable angina, a significantly increased risk was reported for the treatment group (RR=1.24; 95% CI, 1.04 to 1.49; p=0.02).

The NORVIT enrolled 3749 patients with a recent MI and randomized patients to combinations of folate and/or B vitamins.\textsuperscript{26} Patients were followed up for a mean of 3.3 years for the primary outcome, which was a composite of recurrent MI, stroke, and sudden cardiac death. For patients assigned to the active treatment groups, no significant reductions were noted in any of the primary or secondary outcomes. For patients assigned to the combined folate/vitamin B\textsubscript{6}/vitamin B\textsubscript{12} group, an increased risk that was marginally significant (RR=1.22; 95% CI, 1.00 to 1.50; p=0.05) was observed for the primary composite outcome group.

In 2010, findings from the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) in the U.K. were reported.\textsuperscript{27} A total of 12,064 adult patients with a history of MI were randomized to receive folic acid and vitamin B\textsubscript{12} or placebo. An additional eligibility criterion was blood cholesterol of at least 135 mg/dL if taking a statin or 174 mg/dL otherwise. Before randomization, patients participated in a run-in period to confirm that they were adherent to treatment. (Patients were also randomized to receive different doses of simvastatin; those findings are not reported here.) After 3 to 4 years of follow-up, due to the low number of major coronary events in the treatment group, the steering committee (blinded to interim between-group outcomes) decided to change the primary outcome from major coronary events to major vascular events. This composite variable included nonfatal MI, death from CHD, fatal or nonfatal stroke, or any arterial revascularization. After a mean follow-up of 6.7 years, vitamin treatment was not associated with a statistically significant reduction in the primary outcome. The number of major vascular events were 1537 (25.5\%) in the vitamin group and 1493 (24.8\%) in the placebo group (RR=1.04; 95% CI, 0.97 to 1.12). There were no significant differences in risk for any of the components of the composite outcome. In addition, death from all causes did not differ significantly between groups; there were 983 (16.3\%) deaths in the vitamin group and 951 (15.8\%) in the placebo group (RR=1.04; 95% CI, 0.96 to 1.13).

Since the publication of the systematic reviews and meta-analyses described above, van Dijk et al reported results of the B-PROOF trial, an RCT comparing B vitamins (vitamin B\textsubscript{12} 500 mg and folic acid 400 mg) with placebo for improving cardiovascular outcomes among elderly patients with hyperhomocysteinemia.\textsuperscript{28} The study included 2929 subjects over age 65 with an elevated homocysteine level (12-50 µmol/L) who were randomized to 2 years of B vitamin therapy (n=1458) or placebo (n=1461). A random sample of participants (n=569) underwent baseline vascular measurements. Within the vascular subgroup, the aortic pulse pressure after 2 years of intervention was significantly higher in the B vitamin treatment group than in the placebo group (49.6 mm Hg vs 47.2 mm Hg, p=0.02). However, aortic-femoral pulse wave velocity and carotid intima-media thickness did not differ significantly between groups. In the vascular subgroup, serum homocysteine increased by 0.6 µmol/L in the placebo group but decreased by 3.6 µmol/L in the B vitamin therapy group. In the entire study population, the treatment groups did not differ significantly in terms of blood pressure or hypertension incidence, cerebrovascular event incidence, or MI incidence. In subgroup analyses, among women, treatment group subjects had lower incidence of cerebrovascular events than placebo group subjects (OR=0.33; 95% CI, 0.15 to 0.71).
Section Summary: Management Changes and Outcome Improvements Associated With Homocysteine Level Measurements
Numerous large placebo-controlled RCTs have been published that evaluate the impact of folic acid/ vitamin B supplementation on risk of cardiovascular events, including MI and stroke. With few exceptions, meta-analyses of these RCTs have found that homocysteine-lowering interventions do not have a statistically significant effect on the rate of major cardiovascular events. Two meta-analyses of RCTs reported that homocysteine-lowering interventions are associated with improvements in a measure of vascular endothelial function, but it is uncertain whether these changes are associated with improved clinical outcomes.

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 2.

Table 2. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unpublished</td>
<td>Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine in Patients With Mild to Moderate Hypertension, Hyperhomocysteinemia and Angiotensin-Converting Enzyme Inhibitor Intolerance</td>
<td>756</td>
<td>Aug 2014</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

Summary of Evidence
The evidence for the use of homocysteine testing in individuals who are asymptomatic with risk of cardiovascular disease (CVD) or patients with CVD includes of observational studies and randomized controlled trials (RCTs) of homocysteine-lowering interventions. Relevant outcomes are test accuracy and validity, other test performance measures, change in disease status, and morbid events. Observational evidence generally supports the association of homocysteine levels with risk of CVD, especially in patients with preexisting vascular disease. However, evidence from RCTs evaluating homocysteine-lower interventions does not support the hypothesis that lowering homocysteine levels by treatment with folate and/or B vitamins improves cardiovascular outcomes. Numerous large RCTs and meta-analyses of these trials are consistent in reporting that homocysteine-lowering treatment is ineffective in reducing major cardiovascular events. Given the large amount of evidence from placebo-controlled RCTs that homocysteine-lowering interventions do not improve health outcomes, it is unlikely that routine homocysteine testing has the potential to lead to changes in management that improve health outcomes. The evidence is sufficient to determine qualitatively that the technology is unlikely to improve the net health outcome.

Practice Guidelines and Position Statements
In 2013, the American College of Cardiology Foundation and the American Heart Association Task Force on Practice Guidelines issued guidelines on the assessment of cardiovascular risk, which did not address measurement of homocysteine levels.29

U.S. Preventive Services Task Force Recommendations
In 2009, the U.S. Preventive Services Task Force issued a recommendation statement that the evidence is insufficient (1 statement) to assess the benefits and harms of using nontraditional risk factors to screen asymptomatic adults with no history of coronary heart disease (CHD) to
prevent CHD events. Homocysteine was one of the nontraditional risk factors considered in the recommendation. The recommendation statements are currently being updated.

**CODING**

The following codes for treatment and procedures applicable to this policy are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

**CPT/HCPCS**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>83090</td>
<td>Homocysteine</td>
</tr>
</tbody>
</table>

**ICD-9 Diagnoses**

**Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease**

Experimental / investigational for all diagnoses related to this policy.

**Other Homocysteine Testing**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>266.2</td>
<td>Other B-complex deficiencies</td>
</tr>
<tr>
<td>270.4</td>
<td>Disturbance of sulphur-bearing amino-acid metabolism</td>
</tr>
<tr>
<td>281.0</td>
<td>Pernicious anemia</td>
</tr>
<tr>
<td>281.1</td>
<td>Other vitamin B12 deficiency anemia</td>
</tr>
<tr>
<td>281.3</td>
<td>Other specified megaloblastic anemias not elsewhere classified</td>
</tr>
<tr>
<td>286.9</td>
<td>Other and unspecified coagulation defects</td>
</tr>
<tr>
<td>356.4</td>
<td>Idiopathic progressive polyneuropathy</td>
</tr>
<tr>
<td>356.8</td>
<td>Other specified idiopathic peripheral neuropathy</td>
</tr>
<tr>
<td>356.9</td>
<td>Unspecified hereditary and idiopathic peripheral neuropathy</td>
</tr>
<tr>
<td>362.30</td>
<td>Unspecified retinal vascular occlusion</td>
</tr>
<tr>
<td>415.11</td>
<td>Iatrogenic pulmonary embolism and infarction</td>
</tr>
<tr>
<td>415.19</td>
<td>Other pulmonary embolism and infarction</td>
</tr>
<tr>
<td>451.0-451.9</td>
<td>Phlebitis and thrombophlebitis (code range)</td>
</tr>
<tr>
<td>452.0</td>
<td>Portal vein thrombosis</td>
</tr>
<tr>
<td>453.0</td>
<td>Budd-Chiari syndrome</td>
</tr>
<tr>
<td>453.1</td>
<td>Thrombophlebitis migrans</td>
</tr>
<tr>
<td>453.2</td>
<td>Other venous embolism and thrombosis; of inferior vena cava</td>
</tr>
<tr>
<td>453.3</td>
<td>Other venous embolism and thrombosis; of renal vein</td>
</tr>
<tr>
<td>453.40-453.42</td>
<td>Acute venous embolism and thrombosis of deep vessels of lower extremity (code range)</td>
</tr>
<tr>
<td>453.50-453.52</td>
<td>Chronic venous embolism and thrombosis of deep vessels of lower extremity (code range)</td>
</tr>
<tr>
<td>453.6</td>
<td>Venous embolism and thrombosis of superficial vessels of lower extremity</td>
</tr>
<tr>
<td>453.71-453.79</td>
<td>Chronic venous embolism and thrombosis of other specified vessels (code range)</td>
</tr>
<tr>
<td>453.81-453.89</td>
<td>Acute venous embolism and thrombosis of other specified veins (code range)</td>
</tr>
<tr>
<td>453.9</td>
<td>Other venous embolism and thrombosis; of unspecified site</td>
</tr>
<tr>
<td>557.0</td>
<td>Acute vascular insufficiency of intestine</td>
</tr>
<tr>
<td>629.81</td>
<td>Recurrent pregnancy loss without current pregnancy</td>
</tr>
<tr>
<td>634.00-634.92</td>
<td>Spontaneous abortion (code range)</td>
</tr>
<tr>
<td>646.30</td>
<td>Recurrent pregnancy loss, unspecified as to episode of care</td>
</tr>
<tr>
<td>646.31</td>
<td>Recurrent pregnancy loss, with or without mention of antepartum condition</td>
</tr>
<tr>
<td>646.33</td>
<td>Recurrent pregnancy loss, antepartum condition or complication</td>
</tr>
<tr>
<td>V12.51</td>
<td>Venous thrombosis and embolism</td>
</tr>
</tbody>
</table>
ICD-10 Diagnoses
Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease
Experimental / investigational for all diagnoses related to this policy.

Other Homocysteine Testing
D51.0 Vitamin B12 deficiency anemia due to intrinsic factor deficiency
D51.1 Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria
D51.2 Transcobalamin II deficiency
D51.3 Other dietary vitamin B12 deficiency anemia
D51.8 Other vitamin B12 deficiency anemias
D51.9 Vitamin B12 deficiency anemia, unspecified
D53.1 Other megaloblastic anemias, not elsewhere classified
D68.8 Other specified coagulation defects
D68.9 Coagulation defect, unspecified
D81.818 Other biotin-dependent carboxylase deficiency
D81.819 Biotin-dependent carboxylase deficiency, unspecified
E53.8 Deficiency of other specified B group vitamins
E72.10 Disorders of sulfur-bearing amino-acid metabolism, unspecified
E72.11 Homocystinuria
E72.12 Methylene tetrahydrofolate reductase deficiency
E72.19 Other disorders of sulfur-bearing amino-acid metabolism
G60.3 Idiopathic progressive neuropathy
G60.8 Other hereditary and idiopathic neuropathies
G60.9 Hereditary and idiopathic neuropathy, unspecified
H34.8110 Central retinal vein occlusion, right eye, with macular edema
H34.8111 Central retinal vein occlusion, right eye, with retinal neovascularization
H34.8112 Central retinal vein occlusion, right eye, stable
H34.8120 Central retinal vein occlusion, left eye, with macular edema
H34.8121 Central retinal vein occlusion, left eye, with retinal neovascularization
H34.8122 Central retinal vein occlusion, left eye, stable
H34.8130 Central retinal vein occlusion, bilateral, with macular edema
H34.8131 Central retinal vein occlusion, bilateral, with retinal neovascularization
H34.8132 Central retinal vein occlusion, bilateral, stable
H34.8310 Tributary (branch) retinal vein occlusion, right eye, with macular edema
H34.8311 Tributary (branch) retinal vein occlusion, right eye, with retinal neovascularization
H34.8312 Tributary (branch) retinal vein occlusion, right eye, stable
H34.8320 Tributary (branch) retinal vein occlusion, left eye, with macular edema
H34.8321 Tributary (branch) retinal vein occlusion, left eye, with retinal neovascularization
H34.8322 Tributary (branch) retinal vein occlusion, left eye, stable
H34.8330 Tributary (branch) retinal vein occlusion, bilateral, with macular edema
H34.8331 Tributary (branch) retinal vein occlusion, bilateral, with retinal neovascularization
H34.8332 Tributary (branch) retinal vein occlusion, bilateral, stable
I26.09 Other pulmonary embolism with acute cor pulmonale
I26.90 Septic pulmonary embolism without acute cor pulmonale
I26.99 Other pulmonary embolism without acute cor pulmonale
I80.01 Phlebitis and thrombophlebitis of superficial vessels of right lower extremity
I80.02 Phlebitis and thrombophlebitis of superficial vessels of left lower extremity
I80.03 Phlebitis and thrombophlebitis of superficial vessels of lower extremities, bilateral
- Phlebitis and thrombophlebitis of right femoral vein (I80.11)
- Phlebitis and thrombophlebitis of left femoral vein (I80.12)
- Phlebitis and thrombophlebitis of femoral vein, bilateral (I80.13)
- Phlebitis and thrombophlebitis of unspecified deep vessels of right lower extremity (I80.201)
- Phlebitis and thrombophlebitis of unspecified deep vessels of left lower extremity (I80.202)
- Phlebitis and thrombophlebitis of unspecified deep vessels of lower extremities, bilateral (I80.203)
- Phlebitis and thrombophlebitis of right iliac vein (I80.211)
- Phlebitis and thrombophlebitis of left iliac vein (I80.212)
- Phlebitis and thrombophlebitis of iliac vein, bilateral (I80.213)
- Phlebitis and thrombophlebitis of right popliteal vein (I80.221)
- Phlebitis and thrombophlebitis of left popliteal vein (I80.222)
- Phlebitis and thrombophlebitis of popliteal vein, bilateral (I80.223)
- Phlebitis and thrombophlebitis of right tibial vein (I80.231)
- Phlebitis and thrombophlebitis of left tibial vein (I80.232)
- Phlebitis and thrombophlebitis of tibial vein, bilateral (I80.233)
- Phlebitis and thrombophlebitis of other deep vessels of right lower extremity (I80.291)
- Phlebitis and thrombophlebitis of other deep vessels of left lower extremity (I80.292)
- Phlebitis and thrombophlebitis of other deep vessels of lower extremity, bilateral (I80.293)
- Phlebitis and thrombophlebitis of other sites (I80.8)

- Portal vein thrombosis (I81)
- Budd-Chiari syndrome (I82.0)
- Thrombophlebitis migrans (I82.1)
- Acute embolism and thrombosis of superior vena cava (I82.210)
- Chronic embolism and thrombosis of superior vena cava (I82.211)
- Acute embolism and thrombosis of inferior vena cava (I82.220)
- Chronic embolism and thrombosis of inferior vena cava (I82.221)
- Acute embolism and thrombosis of other thoracic veins (I82.290)
- Chronic embolism and thrombosis of other thoracic veins (I82.291)
- Embolism and thrombosis of renal vein (I82.3)
- Acute embolism and thrombosis of unspecified deep veins of right lower extremity (I82.401)
- Acute embolism and thrombosis of unspecified deep veins of left lower extremity (I82.402)
- Acute embolism and thrombosis of unspecified deep veins of lower extremity, bilateral (I82.403)
- Acute embolism and thrombosis of right femoral vein (I82.411)
- Acute embolism and thrombosis of left femoral vein (I82.412)
- Acute embolism and thrombosis of iliac vein, bilateral (I82.413)
- Acute embolism and thrombosis of right tibial vein (I82.421)
- Acute embolism and thrombosis of left tibial vein (I82.422)
- Acute embolism and thrombosis of popliteal vein, bilateral (I82.431)
- Acute embolism and thrombosis of left popliteal vein (I82.432)
- Acute embolism and thrombosis of tibial vein, bilateral (I82.433)
- Acute embolism and thrombosis of other specified deep vein of right lower extremity (I82.491)
- Acute embolism and thrombosis of other specified deep vein of left lower extremity (I82.492)
- Acute embolism and thrombosis of other specified deep vein of lower extremity, bilateral (I82.493)
- Acute embolism and thrombosis of unspecified deep veins of right proximal lower extremity (I82.4Y1)
- Acute embolism and thrombosis of unspecified deep veins of left proximal lower extremity (I82.4Y2)
- Acute embolism and thrombosis of unspecified deep veins of proximal lower extremity, bilateral (I82.4Y3)
I82.4Z1 Acute embolism and thrombosis of unspecified deep veins of right distal lower extremity
I82.4Z2 Acute embolism and thrombosis of unspecified deep veins of left distal lower extremity
I82.4Z3 Acute embolism and thrombosis of unspecified deep veins of distal lower extremity, bilateral
I82.511 Chronic embolism and thrombosis of right femoral vein
I82.512 Chronic embolism and thrombosis of left femoral vein
I82.513 Chronic embolism and thrombosis of femoral vein, bilateral
I82.521 Chronic embolism and thrombosis of right iliac vein
I82.522 Chronic embolism and thrombosis of left iliac vein
I82.523 Chronic embolism and thrombosis of iliac vein, bilateral
I82.531 Chronic embolism and thrombosis of right popliteal vein
I82.532 Chronic embolism and thrombosis of left popliteal vein
I82.533 Chronic embolism and thrombosis of popliteal vein, bilateral
I82.541 Chronic embolism and thrombosis of right tibial vein
I82.542 Chronic embolism and thrombosis of left tibial vein
I82.543 Chronic embolism and thrombosis of tibial vein, bilateral
I82.591 Chronic embolism and thrombosis of other specified deep vein of right lower extremity
I82.592 Chronic embolism and thrombosis of other specified deep vein of left lower extremity
I82.593 Chronic embolism and thrombosis of other specified deep vein of lower extremity, bilateral
I82.5Y1 Chronic embolism and thrombosis of unspecified deep veins of right proximal lower extremity
I82.5Y2 Chronic embolism and thrombosis of unspecified deep veins of left proximal lower extremity
I82.5Y3 Chronic embolism and thrombosis of unspecified deep veins of proximal lower extremity, bilateral
I82.5Z1 Chronic embolism and thrombosis of unspecified deep veins of right distal lower extremity
I82.5Z2 Chronic embolism and thrombosis of unspecified deep veins of left distal lower extremity
I82.5Z3 Chronic embolism and thrombosis of unspecified deep veins of distal lower extremity, bilateral
I82.601 Acute embolism and thrombosis of unspecified veins of right upper extremity
I82.602 Acute embolism and thrombosis of unspecified veins of left upper extremity
I82.603 Acute embolism and thrombosis of unspecified veins of upper extremity, bilateral
I82.611 Acute embolism and thrombosis of superficial veins of right upper extremity
I82.612 Acute embolism and thrombosis of superficial veins of left upper extremity
I82.613 Acute embolism and thrombosis of superficial veins of upper extremity, bilateral
I82.621 Acute embolism and thrombosis of deep veins of right upper extremity
I82.622 Acute embolism and thrombosis of deep veins of left upper extremity
I82.623 Acute embolism and thrombosis of deep veins of upper extremity, bilateral
I82.701 Chronic embolism and thrombosis of unspecified veins of right upper extremity
I82.702 Chronic embolism and thrombosis of unspecified veins of left upper extremity
I82.703 Chronic embolism and thrombosis of unspecified veins of upper extremity, bilateral
I82.711 Chronic embolism and thrombosis of superficial veins of right upper extremity
I82.712 Chronic embolism and thrombosis of superficial veins of left upper extremity
I82.713 Chronic embolism and thrombosis of superficial veins of upper extremity, bilateral
I82.721 Chronic embolism and thrombosis of deep veins of right upper extremity
I82.722 Chronic embolism and thrombosis of deep veins of left upper extremity
I82.723 Chronic embolism and thrombosis of deep veins of upper extremity, bilateral
I82.811 Embolism and thrombosis of superficial veins of right lower extremity
I82.812 Embolism and thrombosis of superficial veins of left lower extremity
I82.813 Embolism and thrombosis of superficial veins of lower extremities, bilateral
I82.91 Chronic embolism and thrombosis of unspecified vein
I82.A11 Acute embolism and thrombosis of right axillary vein
I82.A12 Acute embolism and thrombosis of left axillary vein
I82.A13  Acute embolism and thrombosis of axillary vein, bilateral
I82.A21  Chronic embolism and thrombosis of right axillary vein
I82.A22  Chronic embolism and thrombosis of left axillary vein
I82.A23  Chronic embolism and thrombosis of axillary vein, bilateral
I82.B11  Acute embolism and thrombosis of right subclavian vein
I82.B12  Acute embolism and thrombosis of left subclavian vein
I82.B13  Acute embolism and thrombosis of subclavian vein, bilateral
I82.B21  Chronic embolism and thrombosis of right subclavian vein
I82.B22  Chronic embolism and thrombosis of left subclavian vein
I82.B23  Chronic embolism and thrombosis of subclavian vein, bilateral
I82.C11  Acute embolism and thrombosis of right internal jugular vein
I82.C12  Acute embolism and thrombosis of left internal jugular vein
I82.C13  Acute embolism and thrombosis of internal jugular vein, bilateral
I82.C21  Chronic embolism and thrombosis of right internal jugular vein
I82.C22  Chronic embolism and thrombosis of left internal jugular vein
I82.C23  Chronic embolism and thrombosis of internal jugular vein, bilateral
K55.011  Focal (segmental) acute (reversible) ischemia of small intestine
K55.012  Diffuse acute (reversible) ischemia of small intestine
K55.019  Acute (reversible) ischemia of small intestine, extent unspecified
K55.021  Focal (segmental) acute infarction of small intestine
K55.022  Diffuse acute infarction of small intestine
K55.029  Acute infarction of small intestine, extent unspecified
K55.031  Focal (segmental) acute (reversible) ischemia of large intestine
K55.032  Diffuse acute (reversible) ischemia of large intestine
K55.039  Acute (reversible) ischemia of large intestine, extent unspecified
K55.041  Focal (segmental) acute infarction of large intestine
K55.042  Diffuse acute infarction of large intestine
K55.049  Acute infarction of large intestine, extent unspecified
N96  Recurrent pregnancy loss
O03.2  Embolism following incomplete spontaneous abortion
O03.35  Other venous complications following incomplete spontaneous abortion
O03.39  Incomplete spontaneous abortion with other complications
O03.4  Incomplete spontaneous abortion without complication
O03.7  Embolism following complete or unspecified spontaneous abortion
O03.85  Other venous complications following complete or unspecified spontaneous abortion
O03.88  Urinary tract infection following complete or unspecified spontaneous abortion
O03.89  Complete or unspecified spontaneous abortion with other complications
O03.9  Complete or unspecified spontaneous abortion without complication
O26.21  Pregnancy care for patient with recurrent pregnancy loss, first trimester
O26.22  Pregnancy care for patient with recurrent pregnancy loss, second trimester
O26.23  Pregnancy care for patient with recurrent pregnancy loss, third trimester
T81.72xA  Complication of vein following a procedure, not elsewhere classified, initial encounter
T81.72xD  Complication of vein following a procedure, not elsewhere classified, subsequent encounter
T81.72xS  Complication of vein following a procedure, not elsewhere classified, sequela
Z86.718  Personal history of other venous thrombosis and embolism

**REVISIONS**
08-17-2010  The Homocysteine Testing and Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease medical policies were merged and entitled Homocysteine Testing.
### Description Section updated.

#### In Policy Section:
- Added the following medically necessary non-cardiac indications for testing
  - recurrent pregnancy loss
  - venous thromboembolism
- Clarified that homocysteine testing for any diagnosis other than homocystinuria, recurrent pregnancy loss, borderline vitamin B12 deficiency, or venous thromboembolism is considered E/I by adding, "Homocysteine Testing is considered **experimental / investigational** for any other diagnoses."

### Rationale Section updated.

#### In Coding Section:
- Added Diagnosis codes: 281.0, 281.1, 281.3, 286.9, 356.4, 356.8, 356.9, 362.30, 415.11, 415.19, 444.0-444.1, 444.9, 451.0-451.9-, 452, 453.0, 453.1, 453.2, 453.3, 453.40-453.9, 454.0-454.9, 557.0, 629.81, 634.00-634.92, 646.30, 646.31, 646.33, V12.51

#### References Section updated.

08-12-2011
#### Description section updated.

#### Rationale section updated.

#### In Coding section:
- Broke out the diagnosis coding range 453.40-453.9 to provide more detailed nomenclature
- Updated wording for diagnosis codes: 629.81, 646.30, 646.31, 646.33
- No coding changes were made

#### References updated.

06-29-2012
#### Description section updated.

#### Rationale section updated.

#### In Coding section:
- Diagnosis coding nomenclature updated

#### References updated.

03-31-2014
#### Description section updated.

#### Rationale section updated.

#### In Coding section:
- Removed ICD-9 Diagnoses codes: 444.01-444.1, 444.9, 454.0-454.9
- ICD-10 Diagnoses codes added

#### References updated.

02-24-2016
#### Description section updated.

#### Rationale section updated.

#### In Coding section:
- Revise ICD-10 Code Nomenclature: I82.811, I82.812

10-01-2016

#### In Coding section:
- ICD-10 Codes Effective 10-01-2016: H34.8110, H34.8111, H34.8112, H34.8120, H34.8121, H34.8122, H34.8130, H34.8131, H34.8132, H34.8310, H34.8311, H34.8312, H34.8320, H34.8321, H34.8322, H34.8330, H34.8331, H34.8332, K55.011, K55.012, K55.019, K55.021, K55.022, K55.029, K55.031, K55.032, K55.039, K55.041, K55.042, K55.049
- ICD-10 Codes Termed 09-30-2016: H34.9, K55.0
REFERENCES

1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). C-reactive protein as a cardiac risk marker (special report). TEC Assessments. 2002; Volume 17 Tab 23.


